ADA 2020: CGM Maker Dexcom Gains CE Mark, Launches G6 Pro While Rivalry With Abbott Builds
Dexcom’s CEO explained the company’s strategy for continued growth, including marketing opportunities for its G6 and G6 Pro continuous glucose monitors and plans for the next-gen G7 CGM.
You may also be interested in...
Dexcom expects 2020 revenues to reach $1.85bn driven by new patient adoption of its CGM device, but will not launch its next-gen G7 this year.
Research presented at this year’s virtual American Diabetes Association meeting demonstrated the benefits of continuous glucose monitoring for those with type 2 diabetes not taking insulin. Mahmood Kazemi, divisional VP for global medical and scientific affairs at Abbott’s diabetes care tells Medtech Insight how he sees CGM technology transforming the future of diabetes management.
After announcing positive results at the American Diabetes Association conference and an expanded FDA approval for its insulin pump delivery system, Tandem Diabetes Care’s CEO outlines its path forward.